Latest Commentary

Fourth of July gives FiercePharma the freedom to celebrate

FiercePharma will honor the day by taking a break. We'll be back Thursday with more from the world of drugs and drugmaking.

New week, new winner in the top pharma settlements contest

Last week, when we unveiled our Top 10 Pharma Settlements report, we promised to update it as new deals hit the news. We didn't realize we'd need to fulfill that promise so quickly. Today, GlaxoSmithKline officially announced its $3 billion settlement, which puts it squarely on top of that list.

Pharma's top 10 marketing settlements top $11B

The Justice Department is growing more and more impatient. For more than a decade, its lawyers and investigators have been slapping drugmakers around for their marketing misdoings. They've insisted on bigger and bigger penalties, especially during the last several years, with payments commonly topping $500 million. And yet the whistleblower lawsuits and off-label settlements keep coming.

Pharma herd faces hurdles with pricey new drugs

With drugmakers flocking to lucrative drug markets for specialty care drugs, the bar has risen to get reimbursement and physician uptake of the expensive products. But there are ways to hedge bets in the specialty care game. We covered several such strategies during a panel I moderated at the 2012 BIO International Convention called "Are Healthcare Reimbursement Policies a Barrier to Specialty Care Treatment?" The easy answer to this question is "yes."

FiercePharma is going to Boston for BIO 2012

The FiercePharma team will be relocating to Boston next week for the BIO 2012 International Convention. We are bringing a team of 15 to the show and we'll have daily coverage of the week's events.

Pharma's Top 5 Golden Handshakes of the Last 5 Years

It's an all-too-familiar frustration for pharma shareholders. On the heels of declining revenues and mismanagement, a CEO departs, and then comes the golden handshake.

Who's the sheriff in lab-diagnostics town?

To know that specialized, targeted drugs are pharma's current rallying cry, you didn't have to follow the news out of this month's big cancer meeting. But it's the latest example of how drugmakers are using knowledge of cancer's genetic drivers to develop new treatments.

While we are off for holiday weekend, cargo thieves are not

FiercePharma will not publish Monday because of the Memorial Day holiday, but remember, while most of us are taking a winding down, cargo thieves will be gearing up. The three-day Memorial Day...

Top 10 Best-selling Cancer Drugs in 2011

Oncology drugs are hot. Scratch beneath the surface of most major drugmakers, and you'll find a host of them in various stages of development.

Who's missing from the CEO pay list? Short answer: Europeans

After we assembled this year's ranking of pharma's highest-paid CEOs, we took attendance. And as usual, the absences were telling.